RxDoctor Payments Data

Molly Spearing, NP

Nurse Practitioner · Indianapolis, INNPI 1174616379

Payments from drug & device makers

$463in general payments, 2019–2025

Across 13 payments — averaging $35.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$141
  • AstraZeneca$138
  • Pfizer$45
  • Bayer$29
  • AbbVie$27
  • Exact Sciences$23
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk2$141
AstraZeneca2$138
Pfizer2$45
Bayer1$29
AbbVie2$27
Exact Sciences1$23
Lilly USA, LLC1$22
Amgen1$20
Abbott1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$463 in reported general payments places this provider in the 60th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$101,423
Medicare patients
422
Services billed
1,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$81,729
MounjaroTirzepatide73$80,904
JardianceEmpagliflozin41$33,838
JanuviaSitagliptin Phosphate24$25,793
EliquisApixaban31$25,354
Repatha SureclickEvolocumab23$22,319
FarxigaDapagliflozin Propanediol13$10,594
Janumet XrSitagliptin Phos/Metformin Hcl13$9,912
Valsartan96$2,109
Amlodipine Besylate220$1,556
Nebivolol Hcl16$1,414
Bupropion XlBupropion Hcl61$1,400
Atorvastatin Calcium157$1,274
Ezetimibe56$1,268
Metoprolol Succinate92$1,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$141$81,72975 claims
Lilly USA, LLCMounjaro$22$80,90473 claims
PfizerEliquis$45$25,35431 claims
AstraZenecaFarxiga$138$10,59413 claims
AbbVieSynthroid$27$1,11111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →